I-Adelaide, AU & North Carolina, USA, Mar 28, 2024 โ (ACN Newswire) โ I-Avance Clinical, i-CRO ehamba phambili emakethe yase-Australia naseNyakatho Melika ye-biotechs, izothamela i-World Vaccine Congress e-Washington DC (April 1-4, 2024) futhi yabelane ngezindaba zakamuva zeklayenti lesilingo somtholampilo okuhlanganisa nesimemezelo se-Uvax Bio. (Ibhokisi #267)
Isikhulu se-Avance Clinical, u-Yvonne Lungershausen uthe i-World Vaccine Congress iwumcimbi obalulekile emaqenjini ale nkampani ase-US nase-Australia njengoba eqhubeka nokwenza kahle ezinsizeni zokugomela i-biotech CRO.
U-Lungershausen uthe i-Avance Clinical iyi-CRO emaphakathi, eshesha futhi esabelayo enomlando ofakazelwe wokuthuthukisa ngokushesha izinhlelo zomtholampilo ezisezingeni eliphezulu. "Lokhu kusenza sibe nguzakwethu ofanelekile we-CRO kuma-biotech agxile ekugomeni," kusho yena. ULungershausen uthe inkampani ibe nempumelelo enkulu yekhasimende lokugoma ezifweni ezithathelwanayo, okuhlanganisa i-COVID-19 ne-RSV, kanye nezinye izifo ezifana ne-Hypertension ne-Psoriasis.
Uthe i-Avance Clinical iyaziqhenya ngokusebenzisana nezinkampani eziningi ezintsha zokugomela i-biotech kuhlanganisa Uvax Bio abasanda kumemezela enye ingqopha-mlando ocwaningweni lwabo lwe-HIV lweSigaba I. UMary Giffear, Umqondisi Wokusebenza Komtholampilo we-Uvax Bio ubike, โsiqedile ukubhalisa ocwaningweni lwethu lweSigaba 1 lwabantu abazogomela i-HIV-1 yeNkampani, i-UVAX-1107 kanye ne-UVAX-1197, futhi uhlolo olusekelwe e-Australia lusesikhathini.
U-Lungershausen uthe i-Avance Clinical igxile ekusheshiseni ukuthuthukiswa kwezidakamizwa kumakhasimende ayo e-biotech, kusukela ezigabeni zangaphambi komtholampilo kuye kwiSigaba III.
โLokhu okwethu I-GlobalReady futhi sinamakhasimende angaphezu kuka-90 e-biotech asebenzisa le nqubo eyingqayizivele, ehlelekile yezifunda eziningi. Ngesu lembulunga yonke, siqinisekisa ukusebenza kahle kuzo zonke izinyathelo,โ kusho yena.
โAma-Biotechs afuna uzakwethu ongasiza ngokukhululekile ukuwashintsha onekhono lokuqala ngokushesha ngedatha yekhwalithi ephezulu eyamukelwa kalula yi-US Food and Drug Administration (FDA) nezinye izinhlaka ezilawulayo. Ithimba lethu lezindaba ezilawula umhlaba wonke langaphakathi lisiza ama-biotechs ukuthi azulazule ezinkingeni zokulawula ngokuzethemba futhi asebenzele ukusekela amakhasimende ethu ngokuthunyelwe kwe-FDA, EMA kanye ne-TGA,โ kusho yena.
โNgaphezu kwalokho, wethu I-GlobalReady Site Partnership Network ezingaphezu kuka-1,250 amasayithi afaneleke kakhulu kulo lonke elase-United States aqinisekisa ukusebenza kahle okuphezulu nokusebenza kahle ezivivinyweni zethu zomtholampilo ze-biotech,โ kusho yena.
Enye inzuzo ebalulekile yama-biotechs okugoma ukuthi i-Avance Clinical igunyaziwe njengobuchwepheshe bofuzo i-CRO eyivumela ukuthi ilawule izivivinyo zangaphambi komtholampilo nezomtholampilo zemithi yokugoma kanye nokwelashwa kwe-GMO.
Ihhovisi LeGene Technology Regulator (OGTR) lenze imithethonqubo ethobela umhlaba wonke kanye nokugunyazwa okuhambisana neziqondiso zamazwe ngamazwe.
Isikhulu Esiyinhloko Sezesayensi se-Avance Clinical uDkt. Gabriel Kremmidiotis uthe: โLokhu kusho ukuthi njenge-OGTR egunyazwe i-CRO singakwazi ukusekela amaklayenti ethu e-biotech wamazwe ngamazwe ngolwazi olubanzi lwe-OGTR nolwazi lokusheshisa ucwaningo lwawo lomtholampilo. Ngempela, singakuphikisa ukucaciswa kwemithetho ye-OGTR kwenza i-Australia ibe enye yezindawo ezikhanga kakhulu ocwaningweni lwe-Cell and Gene Technology, โkusho yena.
Thola okuningi:
- Funda nge- Imodeli ye-GlobalReady
- Ukuze uthole ulwazi olwengeziwe mayelana nezinzuzo zokusebenzisa isifundo sakho esilandelayo nge-Avance Clinical Xhumana nathi
- Cela Isiphakamiso lapha
Oxhumana nabo abezindaba:
I-Avance Clinical
[i-imeyili ivikelwe]
Kate Thompson
I-Avance Clinical iyisevisi egcwele enkulu kunazo zonke yase-Australia naseNyakatho Melika ye-CRO eletha izivivinyo zomtholampilo zekhwalithi, ezinedatha eyamukelwa emhlabeni wonke, e-Australia, eNew Zealand nase-US yama-biotechs ngamazwe ngamazwe. Amakhasimende enkampani angama-biotech aqeda Isigaba I kuya kuSigaba sesi-III sohlelo lwawo lokuthuthukisa izidakamizwa oludinga izinsiza zocwaningo lomtholampilo ezisheshayo, ezisheshayo, neziguquguqukayo.
Imiklomelo yeFrost & Sullivan
I-Avance Clinical, umamukeli we-Frost & Sullivan Asia-Pacific CRO Market Leadership Award eminyakeni emine edlule, ubelokhu ehlinzeka ngezinsizakalo ze-CRO esifundeni iminyaka engaphezu kwe-26.
Ukwelashwa kwangaphambi komtholampilo kuya phakathi nesigaba sekwephuzile
I-Avance Clinical inikezela ngezinsizakalo zomtholampilo nethimba labo le-ClinicalReady elinolwazi kusukela ekuqaleni komtholampilo kuya ku-Phase III izinsiza zomtholampilo ezithola izaphulelo ezibalulekile zikaHulumeni wase-Australia ezifika ku-43.5% kanye nezinqubo zokulawula ukuqalisa ngokushesha.
Ngokuhlangenwe nakho kuzo zonke izinkomba ezingaphezu kuka-120, i-CRO ingaletha imiphumela esezingeni lomhlaba kanye nedatha yekhwalithi ephezulu eyamukelwa emhlabeni wonke yokubuyekezwa kwe-FDA ne-EMA.
Ubuchwepheshe
I-Avance Clinical isebenzisa ubuchwepheshe besimanje kanye nezinhlelo ezijwayelekile zegolide kuzo zonke izindawo zokusebenza ukuze inikeze amakhasimende izinqubo ezisebenza kahle kakhulu. I-Medidata, i-Oracle, i-TrialHub, i-Certinia, i-Salesforce, i-Zelta ne-Medrio zingabanye nje babambisene bezobuchwepheshe.
Isihloko: Isifinyezo sokukhishwa kwabezindaba
Source: I-Avance Clinical
Imikhakha: I-BioTech, Ezempilo & i-Pharm, Izivivinyo zemitholampilo
https://www.acnnewswire.com
Kusuka ku-Asia Corporate News Network
Imininingwane ยฉ 2024 ACN Newswire. Wonke Amalungelo Agodliwe. Ukuhlukaniswa kwe-Asia Corporate News Network.
- I-SEO Powered Content & PR Distribution. Khuliswa Namuhla.
- I-PlatoData.Network Vertical Generative Ai. Zinike Amandla. Finyelela Lapha.
- I-PlatoAiStream. I-Web3 Intelligence. Ulwazi Lukhulisiwe. Finyelela Lapha.
- I-PlatoESG. Ikhabhoni, I-CleanTech, Amandla, Environment, Ilanga, Ukuphathwa Kwemfucuza. Finyelela Lapha.
- I-PlatoHealth. I-Biotech kanye ne-Clinical Trials Intelligence. Finyelela Lapha.
- Source: https://www.acnnewswire.com/press-release/english/89921/
